LONDON — The benefit of mineralocorticoid receptor antagonists (MRAs) for the treatment of patients with heart failure and mildly reduced or preserved ejection fraction has finally been established in ...
Evidence supporting medications that slow the heart rate (HR), notably beta-blockers, is overwhelming in heart failure (HF) with reduced ejection fraction. Underwhelming, however, is clinical trial ...
Mavacamten, a drug initially developed to treat hypertrophic cardiomyopathy, has shown signs of reducing heart stress in patients with heart failure with preserved ejection fraction. Heart failure ...
Patients with acute decompensated heart failure (ADHF) have significant differences according to left ventricular ejection fraction, according to a study recently published in BMC Cardiovascular ...
Sacubitril/valsartan leads to greater reduction in plasma NT-proBNP levels compared to valsartan alone after stabilization for worsening heart failure in patients with an ejection fraction (EF) above ...
A new national, pharmacy-led cohort of 10 hospital teams is testing pharmacist-driven interventions to improve medication management after hospital discharge. The American Heart Association (AHA) has ...
Favourable safety profile in marked contrast to traditional inotropic therapeuticsAC01 showed rapid and sustained numerical improvements in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results